Provera - Medroxyprogesterone
4 customer reviewsProvera is an oral progestin tablet containing medroxyprogesterone acetate. It is for people who need help regulating uterine bleeding or protecting the endometrium during estrogen therapy. It works by providing progesterone-like activity that stabilises the uterine lining and supports predictable shedding.
What is it?
Provera Tablets contain medroxyprogesterone acetate (often shortened in conversation to medroxyprogesterone), which is a progestin—a lab-made hormone that behaves like the body’s natural progesterone. In a normal menstrual cycle, progesterone helps “steady” the lining of the uterus (the endometrium) after ovulation, and its drop triggers a period. Provera supports that progesterone effect so the lining sheds in a more predictable way, and it can also help protect the endometrium when estrogen is used in hormone replacement therapy [1].
Understanding Medroxyprogesterone Acetate
Medroxyprogesterone acetate is the specific chemical form that makes Provera work. It binds to progesterone receptors and changes gene signalling inside endometrial cells, which reduces ongoing growth of the lining and makes bleeding patterns easier to manage in hormone-imbalance states. In clinical practice, this is why Provera is often chosen when the main goal is endometrial stabilisation rather than contraception.
Composition
Active substance: medroxyprogesterone acetate (a synthetic progestin). Provera is supplied as oral tablets with the stated strength per tablet on the label; tablets also contain standard pharmaceutical excipients used for tablet formation and stability.
How to use?
- Route: oral (swallow tablets with water)
- Abnormal uterine bleeding (due to hormonal imbalance): 5–10 mg by mouth once daily, preferably at the same time each day, with or without food, for 5–10 days.
- Secondary amenorrhea: 5–10 mg by mouth once daily, with or without food, for 10 days.
- Endometrial protection during estrogen therapy (HRT): 5–10 mg by mouth once daily for 12–14 consecutive days per 28‑day cycle, with or without food.
How does it work?
- Route: oral tablets
- Typical dosing to produce a progestin effect on the endometrium: 5–10 mg by mouth once daily, with or without food.
- Timing: take in the evening or at a consistent time each day.
- Duration by indication: 5–10 days (bleeding control), 10 days (amenorrhea), or 12–14 days per 28‑day cycle (endometrial protection with estrogen).
Indications
Provera is prescribed when a clinician wants progesterone-like activity without using natural progesterone itself. The benefit is targeted: it helps regulate the uterine lining and bleeding pattern when hormones are out of balance.
Provera may be used for:
- Secondary amenorrhea (missing periods not caused by pregnancy)
- Abnormal bleeding from the uterus linked to hormonal imbalance
- Menstrual problems, including heavy periods, painful periods, irregular periods, and persistent periods
- Hormone replacement therapy (HRT) in postmenopausal women, to help with menopausal symptoms while reducing the risk of endometrial hyperplasia that can come with estrogen-only therapy
- As part of treatment plans for endometrial cancer, and in selected cases of breast cancer or kidney cancer where tumors are hormone-responsive (this is specialist-led care)
Provera for Menstrual Irregularities
Secondary amenorrhea is often managed by giving a short course of a progestin so the endometrium can shed, which may “reset” bleeding timing. For abnormal uterine bleeding due to hormonal imbalance, the aim is to stop the endometrium from continuously building up and shedding unpredictably. Heavy, painful, irregular, or persistent periods can share that same endometrial instability as a driver, even when symptoms feel very different day to day.
Provera in Hormone Replacement Therapy
In HRT, estrogen can ease menopausal symptoms, yet unopposed estrogen can raise the chance of endometrial hyperplasia in women with a uterus. Adding a progestin like Provera is a standard strategy to lower that risk by counterbalancing estrogen’s effect on the uterine lining [2].
Provera in Cancer Treatment
In oncology, progestins can be used to slow growth in some hormone-dependent cancers. The decision is based on tumour type, receptor status, stage, and the wider plan from an oncology team; dosing and monitoring are different from menstrual-cycle indications.
Comparison
Alternatives to Provera
Alternatives depend on the reason Provera was chosen. Some people are treated with micronized progesterone (a form closer to natural progesterone) when the goal is endometrial support with a different side-effect profile, while others are managed with different progestins, combined hormonal contraceptives, or non-hormonal options for heavy bleeding. In HRT plans, conjugated estrogens may be paired with a progestin strategy to protect the endometrium, and the exact pairing is individualised based on symptoms and risk factors.
A key limitation: switching hormones is not like switching painkillers. Bleeding patterns can take a few cycles to stabilise after a change.
Depo-Provera vs. Oral Provera
| Feature | Oral Provera | Depo-Provera |
|---|---|---|
| Form & administration | Tablet taken by mouth | Injection (clinic-administered) |
| Usual clinical role | Bleeding control, secondary amenorrhea, HRT endometrial protection | Contraception (long-acting) |
| Duration pattern | Short-course or cyclical, depending on plan | Long-acting effect over weeks/months |
If your goal is contraception, clinicians usually discuss injection-specific issues such as delayed return to fertility and bone mineral density monitoring; those points are not interchangeable with oral tablet use.
Contraindications
- Hypersensitivity to medroxyprogesterone acetate
- Current or past thrombosis or thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism)
- Severe liver disease or active liver tumours
- Undiagnosed vaginal bleeding requiring evaluation
- Known or suspected hormone-dependent malignancy (e.g., breast), unless used as part of a specific cancer treatment plan
Not recommended for
Provera may not be suitable if any of these apply to you:
- You are allergic to medroxyprogesterone acetate
- You have ever had a blood clot (such as a clot in the leg or lungs)
- You have serious liver problems
- You have vaginal bleeding that has not been checked by a clinician
- You have (or might have) a hormone-sensitive cancer, unless a specialist is using Provera as part of your cancer treatment plan
Side effects
Most side effects with Provera are related to hormone sensitivity: changes in bleeding pattern, fluid retention, and mood or headache complaints are the ones I hear about most often. Some risks matter more if you already have clotting risk factors, liver disease, or a history of hormone-sensitive cancers.
Common Side Effects
- Irregular bleeding or spotting (often early in treatment)
- Headache (can be mild or migraine-like)
- Dizziness
- Weight changes, often from fluid retention or appetite shift
- Mood changes, including irritability or low mood
- Sleep problems, either insomnia or sleepiness
These effects can feel “random,” yet they often settle once your body adapts to a steadier progestin level.
Less Common and Rare Side Effects
Seek urgent assessment if you develop symptoms that can fit a clot or severe reaction: new one-sided leg swelling, sudden chest pain, coughing blood, severe shortness of breath, facial swelling, or widespread rash. Rarely, hormone medicines can also aggravate liver problems; warning signs can include persistent right‑upper abdominal pain, dark urine, or yellowing of eyes/skin.
Important Warnings and Precautions
Progestins can increase thromboembolic risk in susceptible people, and that risk profile changes a lot based on age, smoking, obesity, immobility, and personal or family clot history. In day-to-day practice, clinicians also screen for migraine with aura and uncontrolled hypertension because these can shift risk–benefit decisions for hormonal therapies. MOHAP-aligned counselling in the UAE focuses on individual risk assessment before starting hormonal medicines rather than “one-size-fits-all” rules [3].
Common mistakes
Taking Provera correctly is usually simple, yet the small mistakes create most of the frustration.
- Starting Provera without clarifying the cause of bleeding. Heavy or persistent bleeding can be hormonal, yet it can also be structural; treating the symptom alone can delay the right work-up.
- Doubling up after a missed dose. This can worsen nausea, dizziness, and breakthrough bleeding.
- Stopping early because spotting started. Spotting can occur early; stopping and restarting tends to prolong irregular bleeding.
- Assuming it works as contraception. Oral Provera tablets are not positioned as a reliable contraceptive method.
- Underestimating mood effects. If you have a depression history, proactive tracking (sleep, appetite, irritability) helps you spot a pattern quickly and report it clearly.
A short sentence that saves trouble: keep a bleeding diary. It helps.
Doctor opinions
In clinical practice, Provera is a “workhorse” progestin when the problem is endometrial instability—spotting that won’t settle, skipped periods that need a planned withdrawal bleed, or endometrial protection during estrogen therapy. Clinicians often prefer it when they need a predictable progestin effect with a schedule that can be started and stopped, rather than a long-acting method.
One thing doctors warn about early: if you start Provera to control abnormal bleeding, the first week can look messier before it looks better. Another real-world point is diagnostic: persistent abnormal uterine bleeding still needs evaluation for structural causes (polyps, fibroids) and not every bleeding pattern is “just hormones.” EMA safety communications around progestins keep the emphasis on using the lowest effective dose for the shortest necessary duration when the indication allows it, and reassessing risk factors over time [5].
Frequently asked questions
With short-course regimens, a withdrawal bleed often occurs a few days after the last tablet rather than during the first doses. Timing varies with baseline hormone levels and how thick the endometrium is at the start. If bleeding does not occur, clinicians usually reassess causes such as pregnancy, thyroid issues, or hypothalamic stress. In 2026 practice guidance used across MOHAP-aligned services, the key is follow-up rather than repeating courses back-to-back without evaluation.
Yes—when estrogen is used in women with a uterus, adding a progestin can reduce the risk of estrogen-driven endometrial hyperplasia. Provera provides that progestin effect by stabilising the endometrium and limiting ongoing proliferation. The schedule (continuous vs cyclic) is personalised to symptoms and bleeding tolerance. This approach aligns with evidence summaries used by the EMA for progestin-containing therapies.
Urgent symptoms include signs that can fit a clot (new leg swelling/pain, chest pain, sudden shortness of breath), severe allergic reaction (facial swelling, difficulty breathing), or severe liver symptoms (jaundice, dark urine with persistent abdominal pain). These are uncommon, yet they matter because delayed care increases harm. WHO safety frameworks for hormonal medicines emphasise recognising thromboembolic symptoms early and acting fast. If you already have clot risk factors, clinicians typically choose a different plan.
Provera can delay a period by keeping progesterone activity high so the uterine lining does not shed on schedule. Spotting happens when the lining becomes unstable from fluctuating hormone levels, late doses, or starting too close to the expected period. Some cycles are also more “sensitive” after stress, weight change, or travel, so breakthrough bleeding is more likely. EMA-reviewed patient information for progestins lists irregular bleeding as a common effect and one that often improves with consistent dosing.
Oral Provera tablets are not positioned as a reliable contraceptive method. People often confuse it with Depo-Provera, an injectable medroxyprogesterone product used for contraception with a long-acting profile. If pregnancy prevention is the goal, clinicians usually recommend methods with established contraceptive dosing and effectiveness data. WHO family planning guidance in 2026 continues to separate oral short-course progestin use from dedicated contraceptive regimens.
Yes. Mood changes (irritability, low mood) and sleep disruption can occur, most often early in treatment or after a dose change. Patients with a history of depression tend to notice this sooner, so tracking sleep and mood for the first 1–2 weeks is practical. If symptoms are severe or persistent, prescribers often adjust the plan rather than pushing through. EMA safety reviews for progestins recognise central nervous system effects like headache and mood change as clinically relevant adverse effects.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Provera — Comparison with alternatives
Provera Current
Estriol Best rated
Ditropan
Danazol
Evecare Best price
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2026). Progestogens: product information and safety overview for medroxyprogesterone acetate formulations. ↑
- World Health Organization (WHO) (2025). Hormone replacement therapy: benefits, risks, and endometrial protection strategies. ↑
- Ministry of Health and Prevention (MOHAP) (2026). Clinical guidance for management of abnormal uterine bleeding and amenorrhea in primary care. ↑
- World Health Organization (WHO) (2026). Medical eligibility criteria for contraceptive use and progestin-related safety considerations. ↑
- European Medicines Agency (EMA) (2025). Assessment report: risk evaluation of thromboembolic events and abnormal bleeding with systemic progestins. ↑